Invasive pneumococcal pneumonia in children 0-24 months old: Does bacterial resistance affect outcome?;Neumonía neumocócica invasiva en niños de 0 a 24 meses: ¿Influye la resistencia bacteriana en la evolución?

Anales de Pediatria

Volumn 69, Issue 3, 2008, Pages 205-209

  Pirez Garcia M C ^a   Giachetto Larraz, G ^a,b   Romero Rostagno, C ^a   Zabala Chain, C ^a   Algorta Rusinol G ^b   Montano Lotito, A ^a   Ferrari Castilla, A M ^a  

^a Centro Hospitalario Pereira Rossell   (Uruguay)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Outcome; Pneumococcal pneumonia; Resistance penicillin

Indexed keywords

AMPICILLIN; AMPICILLIN PLUS CEFOTAXIME; ANTIBIOTIC AGENT; CEFTRIAXONE; CEFTRIAXONE PLUS VANCOMYCINE; PENICILLIN G; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; EMPYEMA; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; TIME SERIES ANALYSIS;

EID: 51449117373     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13125812     Document Type: Article

References (28)

1. Ferrari AM, Pírez MC, Martínez A, Algorta G, Chamorro F, Guala MJ, et al. Evolución de la etiología de la neumonía bacteriana adquirida en la comunidad en niños hospitalizados. Uruguay 1998-2004. Rev Chil Intect. 2007;24:45-52.
2. Hortal M, Algorta G, Bianchi I, Borthagaray I, Cestau T, Camou T, Castro M, et al. Capsular type distribution and susceptibility to antibiotics of Streptococcus pneumoniae clinical strains isolated from Uruguayan children with systemic infections. Pneumococcus Study Group. Microb Drug Resist. 1997;3:159-63.
3. Klugman K. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990;3:171-96.
4. Pírez MC, Martínez O, Ferrari AM, Nairac A, Montano A, Rubio I, et al. Pneumonia. Standard case management in hospitalized children. Uruguay 1997-1998. Pediatr Infect Dis J. 2001;20:283-9.
5. Giachetto G, Pírez MC, Nanni L, Martínez A, Montano A, Algorta G, et al. Ampicillin and penicillin concentration in serum and pleural fluid of hospitalized children with community acquired pneumonia. Pediatr Infect Dis J. 2004;23:625-9.
6. Gutiérrez S, Stewart J, de Oliver N, Gandaro P, García C, Pírez MC, et al. Factores de riesgo de empiema pleural en niños uruguayos menores de 5 años. Rev Chil Pediatr. 2004;75:536-42.
7. Friedland IR. Comparison of the response to antimicrobial therapy penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14:885-90.
8. Kaplan Sh L, Mason EO Jr. Management of infections due to antibiotic resistant Streptococcus pneumoniae. Clin Microbiol Rev. 1998;11:628-44.
9. Falco V, Alimirante B, Jordana Q, Calonge L, del Valle O, Pigrau C, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumoniae: Is penicillin useful against intermediately resistant strains? J Antimicrob Chemother. 2004;54:481-8.
10. a ed. Montevideo: Oficina del Libro; 2005.
11. Isenberg HD. Clinical microbiology procedures handbook. Washington, DC: American Society of Microbiology; 1994.
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; 14th Informational Supplement NCCLS Document M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004.
13. Pírez MC, Berrondo C, Giacometti M, de Miguel M, Pascale I, Algorta G, et al. Neumonía bacteriana adquirida en la comunidad en niños hospitalizados. Arch Pediatr Urug. 2003;74:6-14.
14. Michelow IC, Olsan K, Lozano J, Pollin NK, Duffy LB, Ziegles T, et al. Epidemiology and clinical characteristics of community acquired pneumonia. Pediatrics. 2004;113:701-70.
15. Ferrari AM, Pírez MC, Ferreira A, Rubio I, Montano A, Lojo R, et al. An strategy for the management of hospitalized children with acute lower respiratory infections. Rev Saúde Pública. 2002;36:1-16.
16. Eskola J, Black S, Shinfefield H. Pneumococcal conjugate vaccine. En: Plotkin SA, Orestein WA, editors. Vaccines. 4th ed. Pennsylvania: Saunders; 2004. p. 589-624.
17. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, et al. Post-licensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-9.
18. Kaplan Sh L, Mason EO, Wald ER, Schutze GE, Bradley JS, Tan TQ. Decrease of invasive pneumococcal infections in children among 8 Children's Hospitals in the United States after the introduction of the 7-valent pneumococal conjugate disease. Pediatrics. 2004;113:443-9.
19. Poehling KA, Lafleur BJ, Szilagyi PG, Ecwards KM, Mitchel E, Barth R, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics. 2004;114:755-76.
20. Schultz KD, Fan LL, Pinsky J, Ochoa L, Shith EO, Kaplan SL, et al. Thee changing face of pleural empyemas in children: Epidemiology and management. Pediatrics. 2004;113:1735-40.
21. Tan TQ, Mason EO, Barson WJ, Wald ER, Schutze GE, Bradley JS, et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-non susceptible Streptococcus pneumoniae. Pediatrics. 1998;102:1369-75.
22. Tan TQ, Mason OE, Wald ER, Barson WJ, Schutze GE, Bradley JS, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics. 2002;110:1-6.
23. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al, and the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med. 2000;160:1399-407.
24. File MF. Appropriate use of antimicrobial for drug-resistant pneumonia: Focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;34 Suppl 2:17-26.
25. Moroney JF, Fiore AI, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, et al. Clinical outcome of bacteriemic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 2001;33:797-805.
26. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al, Gambia Pneumococcal Vaccine Trial Group. Efficacy of nine valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia, double-blind placebo-controlled trial. Lancet. 2005;365:1139-46.
27. Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007;25:6164-6.
28. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine. 2007;25:2406-12.